menu
    • menu
    [{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Radiometer Medical ApS","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Radiometer Medical ApS","highestDevelopmentStatusID":"10","companyTruncated":"Nantes University Hospital \/ Radiometer Medical ApS"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Alberta Boehringer Ingelheim Collaboration","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Alberta Boehringer Ingelheim Collaboration","highestDevelopmentStatusID":"8","companyTruncated":"University of Alberta \/ Alberta Boehringer Ingelheim Collaboration"},{"orgOrder":0,"company":"Victory Nutrition International, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Victory Nutrition International, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Victory Nutrition International, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Victory Nutrition International, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Nobilis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xenon","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Nobilis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nobilis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nobilis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LPOXY Therapeutics","sponsor":"5Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LPOXY Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"LPOXY Therapeutics \/ 5Horizons Ventures","highestDevelopmentStatusID":"6","companyTruncated":"LPOXY Therapeutics \/ 5Horizons Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals for Oxygen

    Menu

    Oxygen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LPOXY Therapeutics

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            LPOXY Therapeutics

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : 5Horizons Ventures

                            Deal Size : $28.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            LPOXY Initiates $28M Series A Financing to Fund STOP-Cdiff Pivotal Trial

                            Details : The proceeds will fund the registrational STOP-Cdiff (sidiprev trial on prevention of C. difficile infections) trial for Sidiprev, positioned to become the first prevention against C. difficile.

                            Product Name : Sidiprev

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 03, 2025

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : 5Horizons Ventures

                            Deal Size : $28.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Alberta

                            Country arrow
                            FNCE
                            Not Confirmed

                            University of Alberta

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Alberta Boehringer Ingelheim Collaboration

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

                            Details : Oxygen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 25, 2023

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Alberta Boehringer Ingelheim Collaboration

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Victory Nutrition International, Inc.

                            Country arrow
                            FNCE
                            Not Confirmed

                            Victory Nutrition International, Inc.

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)

                            Details : Oxygen is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2022

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nantes University Hospital

                            Country arrow
                            FNCE
                            Not Confirmed

                            Nantes University Hospital

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase III

                            Sponsor : Radiometer Medical ApS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Nasal Oxygen Therapy to Reduce Postoperative Complications in Ankle Trauma Surgery in At-risk Pati...

                            Details : Oxygen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ankle Fractures.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : Oxygen

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase III

                            Sponsor : Radiometer Medical ApS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nobilis Therapeutics

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Nobilis Therapeutics

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xenon,Nitrogen,Oxygen

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination fo...

                            Details : Nobilis Therapeutics has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with panic disorder (PD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : Xenon,Nitrogen,Oxygen

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth